ERIS Lifesciences Ltd

ERIS Lifescience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

ERIS Lifesciences Ltd

₹ 1,505 2.49%
21 May 2:13 p.m.
eris.co.in BSE: 540596 NSE: ERIS
About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Key Points

Market Position
The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market. [1]

Website BSE NSE
  • Market Cap ₹ 20,500 Cr.
  • Current Price ₹ 1,505
  • High / Low ₹ 1,594 / 816
  • Stock P/E 265
  • Book Value ₹ 185
  • Dividend Yield 0.52 %
  • ROCE 6.94 %
  • ROE 3.07 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company's working capital requirements have reduced from 66.2 days to 28.2 days

Cons

  • Stock is trading at 8.03 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.7% over past five years.
  • Company has a low return on equity of 11.0% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
282 329 355 332 315 411 410 324 341 457 437 400 405
181 203 214 206 203 256 265 250 262 333 294 300 284
Operating Profit 102 126 141 126 111 156 144 74 79 123 143 100 121
OPM % 36% 38% 40% 38% 35% 38% 35% 23% 23% 27% 33% 25% 30%
9 3 6 3 4 4 7 3 20 5 6 8 17
Interest 1 7 7 3 3 7 7 15 29 56 56 55 53
Depreciation 15 15 16 16 17 20 25 28 29 46 46 47 43
Profit before tax 95 107 124 110 96 133 120 35 42 27 46 6 41
Tax % 8% 11% 7% 10% 8% 16% 2% 9% 5% 36% 39% 70% 26%
87 96 115 99 88 111 118 32 40 17 28 2 30
EPS in Rs 6.38 7.03 8.47 7.31 6.46 8.14 8.66 2.33 2.90 1.25 2.06 0.13 2.24
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
520 548 605 713 761 897 1,020 1,109 1,216 1,331 1,487 1,698
436 437 435 442 445 562 661 691 727 825 1,031 1,211
Operating Profit 84 111 171 271 316 334 359 417 488 506 456 487
OPM % 16% 20% 28% 38% 42% 37% 35% 38% 40% 38% 31% 29%
9 7 3 25 28 32 11 10 25 16 33 36
Interest 0 0 0 1 10 23 2 1 3 21 57 220
Depreciation 4 15 20 21 22 32 45 38 51 65 102 182
Profit before tax 89 103 154 274 312 312 324 389 459 437 329 120
Tax % 27% 19% 10% 9% 6% 8% 10% 10% 9% 9% 9% 36%
65 83 138 248 294 285 291 351 417 398 300 77
EPS in Rs 4,738.18 6,060.36 10,034.18 18.05 21.36 20.75 21.45 25.82 30.69 29.27 22.03 5.68
Dividend Payout % 0% 0% 61% 0% 0% 0% 13% 21% 20% 25% 0% 129%
Compounded Sales Growth
10 Years: 12%
5 Years: 11%
3 Years: 12%
TTM: 14%
Compounded Profit Growth
10 Years: 0%
5 Years: -23%
3 Years: -43%
TTM: -74%
Stock Price CAGR
10 Years: %
5 Years: 24%
3 Years: 27%
1 Year: 62%
Return on Equity
10 Years: 20%
5 Years: 15%
3 Years: 11%
Last Year: 3%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.14 0.14 0.14 14 14 14 14 14 14 14 14 14
Reserves 184 267 305 561 854 1,142 1,286 1,562 1,905 2,208 2,510 2,501
0 1 0 0 376 176 0 0 0 317 2,529 2,245
83 86 96 82 126 138 183 179 232 245 296 463
Total Liabilities 268 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 5,350 5,222
64 61 65 92 490 484 601 584 642 898 1,516 2,412
CWIP 0 0 0 0 0 3 4 2 3 0 1 0
Investments 98 182 206 381 546 580 320 531 778 997 1,619 991
106 110 131 184 335 403 558 638 728 889 2,214 1,819
Total Assets 268 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 5,350 5,222

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
90 92 133 210 236 216 265 395 369 322 336 702
-85 -94 -45 -199 -593 2 127 -348 -268 -513 -2,492 -359
-0 1 -84 -18 363 -221 -334 -81 -88 194 2,160 -310
Net Cash Flow 5 -1 4 -6 7 -2 58 -34 13 3 4 32

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 16 16 15 21 29 31 50 37 41 63 59 51
Inventory Days 130 181 156 161 194 206 145 119 155 98 119 140
Days Payable 93 121 88 86 266 207 200 159 177 128 181 158
Cash Conversion Cycle 52 75 84 97 -43 30 -4 -3 19 33 -3 33
Working Capital Days 11 13 8 31 2 -22 58 65 80 82 89 28
ROCE % 56% 44% 53% 62% 35% 26% 24% 27% 27% 20% 10% 7%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
52.30% 52.29% 52.70% 52.86% 52.86% 54.91% 54.90% 54.90% 54.88% 54.87% 54.86% 54.85%
15.35% 15.39% 15.50% 14.86% 13.78% 13.20% 13.13% 14.27% 14.59% 8.01% 8.36% 8.43%
10.66% 10.69% 9.95% 10.02% 10.73% 14.52% 14.55% 15.63% 16.23% 18.64% 18.07% 18.07%
21.69% 21.63% 21.85% 22.27% 22.63% 17.37% 17.41% 15.20% 14.30% 18.47% 18.73% 18.64%
No. of Shareholders 51,63948,05546,74645,93144,16942,24546,49651,75344,17646,34653,31450,087

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls